Catherine M. Bollard, MBChB, MD, FRACP, FRCPA, is a Professor of Immunology and Pediatrics at the Baylor College of Medicine, and a Principal Investigator at the Center for Cancer and Immunology Research at the Children’s Research Institute. childrensnational.org and www.bcm.edu
Dr. Bollard’s research interests involve using cytotoxic T cells (CTL) for viral and malignant diseases. Dr Bollard is a principal investigator on two clinical trials assessing the safety of adoptively transferred donor-derived virus-specific CTL for the prophylaxis and treatment of CMV and adenoviral infection post allogeneic stem cell transplant. She is also evaluating the efficacy of tumor-specific CTL in patients with relapsed EBV positive Hodgkin’s disease and non-Hodgkin Lymphoma. Further, she is developing gene therapy strategies to counteract tumor immune evasion mechanisms to enhance the efficacy of adoptive immunotherapy protocols. Specifically, she demonstrated a method of genetically modifying CTL to improve their potential as cell therapy for Hodgkin Disease. The use of CTL expressing a dominant negative TGF beta receptor mutant is likely to improve cell therapy for patients with not only Lymphoma, but also other cancers that use TGF beta secretion as a means to evade the immune response.